Novel SPECC1L-MET Fusion Detected in Circulating Tumor DNA in a Patient with Lung Adenocarcinoma following Treatment with Erlotinib and Osimertinib

J Thorac Oncol. 2019 Feb;14(2):e27-e29. doi: 10.1016/j.jtho.2018.10.160.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Acrylamides / administration & dosage
  • Adenocarcinoma / drug therapy
  • Adenocarcinoma / genetics*
  • Aged, 80 and over
  • Aniline Compounds / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Calponins
  • Crizotinib / administration & dosage
  • DNA, Neoplasm / blood
  • DNA, Neoplasm / genetics*
  • Disease Progression
  • ErbB Receptors / genetics
  • Erlotinib Hydrochloride / administration & dosage
  • Fatal Outcome
  • Humans
  • Indoles
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / genetics*
  • Male
  • Oncogene Fusion
  • Phosphoproteins / genetics*
  • Proto-Oncogene Proteins c-met / genetics*
  • Pyrimidines

Substances

  • Acrylamides
  • Aniline Compounds
  • Crizotinib
  • DNA, Neoplasm
  • ErbB Receptors
  • Erlotinib Hydrochloride
  • Phosphoproteins
  • Proto-Oncogene Proteins c-met
  • SPECC1L protein, human
  • Calponins
  • osimertinib
  • Indoles
  • Pyrimidines
  • EGFR protein, human
  • MET protein, human